PDA

Archiv verlassen und diese Seite im Standarddesign anzeigen : neue zusätzliche Daten zu Macitentan und Selexipag



card
13.05.2015, 15:03
jeweils im text auf das fett gedruckte "here" clicken :

http://www1.actelion.com/en/our-company/news-and-events.page?newsId=1920801&bb=js

Hope
27.08.2015, 07:28
http://www.finanzen.net/nachricht/aktien/Weitere-Daten-zu-Selexipag-Uptravi-und-Macitentan-Opsumit-anlaesslich-des-Jahreskongresses-2015-der-Europaeischen-Gesellschaft-fuer-Kardiologie-vorgestellt-4492302

Abstract:

http://spo.escardio.org/SessionDetails.aspx?eevtid=1085&sessId=16488&subSessId=0&searchQuery=%2fdefault.aspx%3feevtid%3d1085%26days %3d%26topics%3d%26types%3d%26rooms%3d%26freetext%3 dselexipag%26sort%3d1%26page%3d1%26showResults%3dT rue%26nbPerPage%3d20%26WithWebcast%3d%26WithSlides %3d%26WithAbstract%3d%26WithReport%3d%26scroll%3D0 #.Vdr7KPmVLxo

Poster: P2365

card
27.08.2015, 10:01
Abstract:

http://spo.escardio.org/SessionDetails.aspx?eevtid=1085&sessId=16488&subSessId=0&searchQuery=%2fdefault.aspx%3feevtid%3d1085%26days %3d%26topics%3d%26types%3d%26rooms%3d%26freetext%3 dselexipag%26sort%3d1%26page%3d1%26showResults%3dT rue%26nbPerPage%3d20%26WithWebcast%3d%26WithSlides %3d%26WithAbstract%3d%26WithReport%3d%26scroll%3D0 #.Vdr7KPmVLxo

Poster: P2365

For the first time, a clinically relevant benefit on long-term outcomes has been shown when adding a third PAH drug on top of double combination therapy.